Tuberous Sclerosis Complex: A Roadmap for Future Research
- PMID: 27617567
- PMCID: PMC5005288
- DOI: 10.15844/pedneurbriefs-30-7-1
Tuberous Sclerosis Complex: A Roadmap for Future Research
Abstract
Investigators from the NINDS and the Tuberous Sclerosis Alliance sponsored a workshop in March 2015, which joined basic scientists and clinicians with expertise in various aspects of Tuberous Sclerosis Complex (TSC), in order to assess the current state of TSC research and to set future goals.
Keywords: Autism; Epilepsy; Tuberous Sclerosis Complex; mTOR.
Comment on
-
Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.Pediatr Neurol. 2016 Jul;60:1-12. doi: 10.1016/j.pediatrneurol.2016.03.015. Epub 2016 Apr 2. Pediatr Neurol. 2016. PMID: 27267556 Free PMC article.
References
-
- Sahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, et al. Tuberous Sclerosis Complex Working Group to Update the Research Plan. Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatr Neurol. 2016 Jul;60:1–12. doi: 10.1016/j.pediatrneurol.2016.03.015. - DOI - PMC - PubMed
-
- Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013 Jan;381(9861):125–32. doi: 10.1016/S0140-6736(12)61134-9. - DOI - PubMed
-
- Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013 Mar;381(9869):817–24. doi: 10.1016/S0140-6736(12)61767-X. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous